Entero Healthcare Solutions Limited share price
NSE: ENTERO · ISIN INE010601016
Key numbers
- Market cap
- ₹ 7,929 Cr
- Current price
- ₹ 1,821.80
- 52-week high / low
- ₹ 1,920 / 944
- Stock P/E
- 63.5
- Book value
- ₹ 388.1
- Dividend yield
- 0.00%
- ROCE
- 10.2%
- ROE
- 6.7%
- Debt to equity
- 0.40
- Sales growth (3 yrs)
- 25.7%
- Profit growth (3 yrs)
- -
- 1-year return
- 62.2%
About Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| Operating profit | 50 | 62 | 68 | 86 | 97 |
| Net profit | 28 | 32 | 28 | 28 | 38 |
| EPS (₹) | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
Concall summary (2026-08-17)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Having achieved a 5% EBITDA margin in the first quarter itself means we are already tracking well at our full year FY27 guidance.
- We remain firmly committed to our stated FY27 guidance of consolidated revenue growth of approximately 23% year-on-year, excluding any contribution from new acquisitions, alongside an EBITDA margin of 5% and EBITDA to operating cash flow conversion of 50%.
Growth & demand
- Organic revenue growth for the quarter was 17.8% on a reported basis and 19.6% on a like -for-like basis, comfortably ahead of the underlying pharmaceutical market growth of 13.8%.
- Inorganic growth was a t 20.4% and the entirety of this growth came from the calendarization of acquisitions completed in last year.
Margins & costs
- This top line performance was accompanied by continued and meaningful margin improvement with EBITDA margin reaching 5% for the quarter.
- Gross margin expanded 147 basis points year-on-year to 11.4% and EBITDA margin expanded 143 basis points to 5%, while EBITDA growing 94% year -on-year, nearly 2.5x our revenue growth rate.
Capex & expansion
- As many of you are aware, our acquisition structure in few acquisitions involved a majority buy- out, but not a full 100% stake.
- We have a pre-agreed contractually defined call options (subject to certain conditions ) to acquire the residual minority stake over a defined time horizon, exercisable at a valuation multiple, consistent with the multiple paid at the time of original acquisition.
Balance sheet & cash
- And we had also a -- we have taken about INR200 crores of debt for the primarily because of that.
- My question is around -- I believe we have reached to a level where for the incremental 20% plus growth whatever is the incremental working capital required.
Peers in Medical Distribution
Data for information only, not investment advice. Prices end of day.